請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34253
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 邱式鴻 | |
dc.contributor.author | Ming-Hong Chuang | en |
dc.contributor.author | 莊明恆 | zh_TW |
dc.date.accessioned | 2021-06-13T06:00:02Z | - |
dc.date.available | 2007-01-01 | |
dc.date.copyright | 2006-07-05 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-06-26 | |
dc.identifier.citation | 參考資料
1.Marshell, B. J. & Warren, J. R. (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1, 1311-1315. 2.Stults, J. T. & Arnott, D. (2005) Proteomics. Methods Enzymol. 402, 289-312. 3.Kaiser, J. (2002) Proteomics - Public-private group maps out initiatives. Science 296, 827-830. 4.Yates, J.R. (1998) The age of proteome. J. Mass Spectrom. 33, 1-19. 5.Ross, J. S., Symmans, W. F., Pusztai, L. & Hortobagyi, G. N. (2005) Pharmacogenomics and clinical biomarkers in drug discovery and development. Am. J. Clin. Pathol. 124, S29-41. 6.Kelsoe, J. R. (2004) Genomics and the human genome project: implications for psychiatry. Int. Rev. Psychiatry. 16, 294-300. 7.Werner, E. (2005) Genome semantics, in silico multicellular systems and the Central Dogma. FEBS Lett. 579, 1779-1782. 8.Hiendleder, S., Bauersachs, S., Boulesteix, A., Blum, H., Arnold, G. J., Frohlich, T. & Wolf, E. (2005) Functional genomics: tools for improving farm animal health and welfare. Rev. Sci. Tech. 24, 355-377. 9.Reis-Filho, J. S., Westbury, C. & Pierga, J. Y. (2006) The impact of expression profiling on prognostic and predictive testing in breast cancer. J. Clin. Pathol. 59, 225-231. 10.Nygaard, V. & Hovig, E. (2006) Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling. Nucleic Acids Res. 34, 996-1014. 11.Qian, X., Scheithauer, B. W., Kovacs, K. & Lloyd, R. V. (2005) DNA microarrays: recent developments and applications to the study of pituitary tissues. Endocrine. 28, 49-56. 12.Yuan, J. P., Li, T., Chen, H. B., Li, Z. H., Yang, G. Z., Hu, B. Y., Shi, X. D., Yong, S. Q., Li, Y. X. & Guo, X. K. (2004) Analysis of gene expression profile in gastric cancer cells stimulated with Helicobacter pylori isogenic strains. J. Med. Microbiol. 53, 965-974. 13.Baumann, M. & Meri, S. (2004) Techniques for studying protein heterogeneity and post-translational modifications. Expert.Rev. Proteomics. 1, 207-217. 14.Kumar, G. K. & Klein, J. B. (2004) Analysis of expression and posttranslational modification of proteins during hypoxia. J. Appl. Physiol. 96, 1178-1186. 15.Seo, J. & Lee, K. J. (2004) Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J. Biochem. Mol. Biol. 37, 35-44. 16.Carr, S. A., Annan, R. S. & Huddleston, M. J. (2005) Mapping posttranslational modifications of proteins by MS-based selective detection: application to phosphoproteomics. Methods Enzymol. 405, 82-115. 17.Fischer, W. & Haas, R. (2004) The RecA protein of Helicobacter pylori requires a posttranslational modification for full activity. J. Bacteriol. 186, 777-784. 18.Moreno-Arribas, M. V. & Polo, M. C. (2005) Winemaking biochemistry and microbiology: current knowledge and future trends. Crit. Rev. Food. Sci. Nutr. 45, 265-286. 19.Schuller, D. & Casal, M. (2005) The use of genetically modified Saccharomyces cerevisiae strains in the wine industry. Appl. Microbiol. Biotechnol. 68, 292-304. 20.Schuler, G. D., Boguski, M. S., Stewart, F. A., Stein, L. D., Gyapay, G., Rice, K., White, R. E., Rodriguez-Tome, P., Aggarwal, A. et al. (1996) A gene map of the human genome. Science 274, 540-546. 21.Miklos, G. L. & Rubin, G. M. (1996) The role of the genome project in determining gene function: insights from model organisms. Cell 86, 521-529. 22.Cavalli-Sforza, L. L. (2005) The Human Genome Diversity Project: past, present and future.Nat. Rev. Genet. 6, 333-340. 23.Guenet, J. L. (2005) The mouse genome. Genome Res. 15, 1729-1740. 24.Burt, D. W. (2005) Chicken genome: current status and future opportunities. Genome Res. 15, 1692-1698. 25.Ashburner, M. & Bergman, C. M. (2005) Drosophila melanogaster: a case study of a model genomic sequence and its consequences. Genome Res. 15, 1661-1667. 26.Hillier, L. W., Coulson, A., Murray, J. I., Bao, Z., Sulston, J. E. & Waterston, R. H. (2005) Genomics in C. elegans: so many genes, such a little worm. Genome Res. 15, 1651-1660. 27.Chan, S. M. & Utz, P. J. (2005) The challenge of analyzing the proteome in humans with autoimmune diseases. Ann. N. Y. Acad. Sci. 1062, 61-68. 28.Zdebska, E., Musielak, M., Jaeken, J. & Koscielak, J. (2001) Band 3 glycoprotein and glycophorin A from erythrocytes of children with congenital disorder of glycosylation type-Ia are underglycosylated. Proteomics 1, 269-274. 29.Cacabelos, R., Fernandez-Novoa, L., Lombardi, V., Kubota, Y. & Takeda, M. (2005) Molecular genetics of Alzheimer's disease and aging. Methods Find. Exp. Clin. Pharmacol. 27, 1-573. 30.Baldwin, M. A. (2005) Analysis of glycosylphosphatidylinositol protein anchors: the prion protein. Method Enzymol. 405, 172-187. 31.Michel, P. E., Crettaz, D., Morier, P., Heller, M., Gallot, D., Tissot, J. D. Reymond, F. & Rossier, J. S. (2006) Proteome analysis of human plasma and amniotic fluid by Off-Geltrade mark isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis 27, 1169-1181. 32.Asa, S. L. & Ezzat, S. (2005) Genetics and proteomics of pituitary tumors. Endocrine. 28, 43-47. 33.Themmen, A. P. (2005) An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms. Reproduction 130, 263-274. 34.Blake, C. A. & Helmke, S. M. (2005) Proteomics of the anterior pituitary gland as a model for studying the physiology of a heterogeneous organ. Exp. Biol. Med. 230, 793-799. 35.Ross, J. S., Symmans, W. F., Pusztai, L. & Hortobagyi, G. N. (2005) Pharmacogenomics and clinical biomarkers in drug discovery and development. Am. J. Clin. Pathol. 124, 29-41. 36.Ekins, S., Nikolsky, Y. & Nikolskaya, T. (2005) Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 26, 202-209. 37.Everley, P. A. & Zetter, B. R. (2005) Proteomics in tumor progression and metastasis. Ann. N. Y. Acad. Sci. 1059, 1-10. 38.Ross, J. S., Symmans, W. F., Pusztai, L. & Hortobagyi, G. N. (2005) Breast cancer biomarkers. Adv. Clin. Chem. 40, 99-125. 39.Ning, L., Zhang, T. P. & Zhao, Y. P. (2005) Research development of proteomics in pancreatic cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27, 640-643. 40.Stevens,E. V., Posadas, E. M., Davidson, B. & Kohn, E. C. (2004) Proteomics in cancer. Ann. Oncol. 15, 67-71. 41.Tomb,J. F., White, O., Kerlavage, A. R., Clayton, R. A., Sutton, G. G., Fleischmann, R. D. et al. (1997) The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388, 539-547. 42.Hopkins, R. J., Girardi, L. S. & Turney, E. A. (1996) Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence : a review. Gastroenterology 110, 1244-1252 43.Kreiss, C. & Blum, A. L. (1995) Malfertheiner, P. Peptic ulcer pathogenesis. Curr. Opin. Gastroenterol. 11, 25-31. 44.Suerbaum, S. & Michetti, P. (2002) Helicobacter pylori infection. N. Engl. J. Med. 347, 1175-1186. 45.Walker, M. M. & Crabtree, J. E. (1998) Helicobacter pylori infection and the pathogenesis of duodenal ulceration, Ann. N Y Acad. Sci. 859, 96-111 (1998). 46.Blaser, M. J. (1998) Helicobacter pylori and gastric diseases. Biomed. J. 316, 1507-1510. 47.Stoicov, C., Saffari, R., Cai, X., Hasyagar, C. & Houghton, J. M. (2004) Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene 341, 1-17. 48.Aspholm-Hurtig, M., Dailide, G., Lahmann, M., Kalia, A., Ilver, D., Roche, N., Vikstrom, S., Sjostrom, R., Linden, S., Backstrom, A., et al. (2004) Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science 305, 519-522. 49.Hennig, E. E., Mernaugh, R., Edl, J., Cao, P. & Cover, T. L. (2004) Heterogeneity among Helicobacter pylori strains in expression of the outer membrane protein BabA. Infect. Immun. 72, 3429-3435. 50.Backstrom, A., Lundberg, C., Kersulyte, D., Berg, D. E., Boren, T. & Arnqvist, A. (2004) Metastability of Helicobacter pylori bab adhesin genes and dynamics in Lewis b antigen binding. Proc Natl Acad Sci USA 101, 16923-16928. 51.Blaser, M. J. (2005) The biology of cag in the Helicobacter pylori-human interaction. Gastroenterology 128, 1512-1515. 52.Hatakeyama, M. & Higashi, H. (2005) Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci. 96, 835-843. 53.Israel, D. A. & Peek, R. M. (2006) The role of persistence in Helicobacter pylori pathogenesis. Curr. Opin. Gastroenterol. 4, 151-159. 54.Boyle, E. C. & Finlay, B. B. (2003) Bacterial pathogenesis : exploiting cellular adherence. Curr. Opin. Cell. Biol. 15, 633-639. 55.Yoshiyama, H. & Nakazawa, T. (2000) Unique mechanism of Helicobacter pylori for colonizing the gastric mucus. Microbes Infect. 2, 55-60. 56.Lu, H., Yamaoka, Y. & Graham, D. Y. (2005) Helicobacter pylori virulence factors: facts and fantasies. Curr. Opin. Gastroenterol. 21, 653-659. 57.Cover, T. L. & Blanke, S. R. (2005) Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat. Rev. Microbiol. 3, 320-322. 58.de Bernard, M., Cappon, A., Del Giudice, G., Rappuoli, R. & Montecucco, C. (2004) The multiple cellular activities of the VacA cytotoxin of Helicobacter pylori. Int. J. Med. Microbiol. 293, 589-597. 59.Farinha, P. & Gascoyne, R. D. (2005) Helicobacter pylori and MALT lymphoma. Gastroenterology 128, 1579-1605. 60.Wu, M. S. , Shun, C. T. , Wang, H. P. , Sheu, J. C. , Lee, W. J. , et al. (1997) Genetic alterations of gastric cancer relation to histological subtypes, tumor stage, and Helicobacter pylori infection, Gastroenterology 112, 1457-1465. 61.Matsushima, M., Suzuki, T., Kurumada, T., Watanabe, S., Watanabe, K., Kobayashi, K., Deguchi, R., Masui, A.,Takagi, A., Shirai, T. et al. (2006) Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection. J Gastroenterol Hepatol. 21, 232-6. 62.Murakami, K., Sato, R., Okimoto, T., Watanabe, K., Nasu, M., Fujioka, T., Kodama, M., Abe, T., Sato, S. & Arita, T. (2006) Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 21, 262-267. 63.Allen, L. A. H. (2003) Mechaisms of pathogenesis: evasion of killing by polymorphonuclear leukocytes. Microbes Infect. 5, 1329-1335. 64.O’Rourke, E. J., Chevalier, C., Pinto, A. V., Thiberge, J. M., Ielpi, L., Labigne, A. & Radicella, J. P. (2003) Pathogen DNA as target for host-generated oxidative stress: role for repair of bacterial DNA damage in Helicobacter pylori colonization. Proc. Natl. Acad. Sci. U S A. 100, 2789-94. 65.Naito, Y. & Yoshikawa, T. (2002) Molecular and cellular mechanisms involved in Helicobacter pylori-induced inflammation and oxidative stress. Free Radic. Biol. Med. 33, 323-36. 66.Nakamura, A., Park, A. M., Nagata, K., Sato, E. F., Kashiba, M., Tamura, T. & Inoue, M. (2000) Oxidative cellular damage associated with transformation of Helicobacter pylori from a bacillary to a coccoid form. Free Radic. Biol. Med. 28, 1611-1618. 67.Saito, N., Konishi, K., Sato, F., Kato, M., Takeda, H., Sugiyama, T. & Asaka, M. (2003) Plural transformation-processes from spiral to coccoid Helicobacter pylori and its viability. J Infect. 46, 49-55. 68.Olczak, A. A., Wang, G. & Maier, R. J. (2005) Up-expression of NapA and other oxidative stress proteins is a compensatory response to loss of major Helicobacter pylori stress resistance factors. Free, Radic, Res. 39, 1173-1182. 69.Gancz, H., Censini, S. & Merrell, D. S. (2006) Iron and pH homeostasis intersect at the level of Fur regulation in the gastric pathogen Helicobacter pylori. Infect. Immun. 74, 602-614. 70.Wen, Y., Marcus, E. A., Matrubutham, U., Gleeson, M. A., Scott, D. R. & Sachs, G. (2003) Acid-adaptive genes of Helicobacter pylori. Infect. Immun. 71, 5921-5939. 71.Loughlin, M. F. (2003) Novel therapeutic targets in Helicobacter pylori. Expert. Oets. Targets. 7, 725-735. 72.Barnard, F. M., Loughlin, M. F., Fainberg, H. P., Messenger, M. P., Ussery, D. W., Williams, P. & Jenks, P. J. (2004) Global regulation of virulence and the stress response by CsrA in the highly adapted human gastric pathogen Helicobacter pylori. Mol. Microbiol. 51, 15-32. 73.Park, A. M., Li, Q., Nagata, K., Tamura, T., Shimono, K., Sato, E. F. & Inoue, M. (2004) Oxygen tension regulates reactive oxygen generation and mutation of Helicobacter pylori. Free Radic. Biol. Med. 36, 1126-1133. 74.Bagchi, D., Bhattacharya, G. & Stohs, S. J. (1996) Production of reactive oxygen species by gastric cells in association with Helicobacter pylori. Free Radic. Res. 24, 439-450. 75.Olczak, A. A., Olson, J. W. & Maier, R. J. (2002) Oxidative-stress resistance mutants of Helicobacter pylori. J. Bacteriol. 184, 3186-3193. 76.Olczak, A. A., Seyler, R. W., Olson, J. W. & Maier, R. J. (2003) Association of Helicobacter pylori antioxidant activities with host colonization proficiency. Infect. Immun. 71, 580-583. 77.Wang, G., Conover, R. C., Benoit, S., Olczak, A. A., Olson, J. W., Johnson, M. K. & Maier, R. J. (2004) Role of a bacterial organic hydroperoxide detoxification system in preventing catalase inactivation. J. Biol. Chem. 279, 51908-51914. 78.Baker, L. M. S., Raudonikiene, A., Hoffman, P. S. & Poole, L. B. (2001) Essential thioredoxin-dependent peroxiredoxin system from Helicobacter pylori: genetic and kinetic characterization. J Bacteriol. 183, 1961-73. 79.Rabelo-Goncalves, E. M., Nishimura, N. F. & Zeitune, J. M. (2002) Acute inflammatory response in the stomach of BALB/c mice challenged with coccoidal Helicobacter pylori. Mem Inst Oswaldo Cruz. 97, 1201-1206.. 80.Mulrooney, S. B. & Hausinger, R. P. (2003) Nickle uptake and utilization by microorganisms, FEMS Microbiol. Rev. 27, 239-261. 81.Benoit, S. & Maier, R. J. (2003) Dependence of Helicobacter pylori Urease activity on the Nickle-sequestering ability of the UreE accessory protein, J. Bacteriol. 185, 4787-4795. 82.Soriano, A., Colpas, G. J. & Hausinger, R. P. (2000) UreE stimulation of GTP-dependent urease activation in the UreD-UreF-UreG-urease apoprotein complex. Biochemistry 39, 12435-12440. 83.Park, J. U., Song, J. Y., Kwon, Y. C., Chung, M. J., Jun, J. S., Park, J. W., Park, S. G., Hwang, H. R., Choi, S. H., Baik, S. C. et al. (2005) Effect of the urease accessory genes on activation of the Helicobacter pylori urease apoprotein. Mol. Cells. 20, 371-377. 84.Johnson, N. A., Liu, Y. & Fletcher, H. M. (2004) Alkyl hydroperoxide peroxidase subunit C (ahpC) protects against organic peroxides but does not affect the virulence of Porphyromonas gingivalis W83. Oral Microbiol. Immunol. 19, 233-239. 85.Parsonage, D., Youngblood, D. S., Sarma, G. N., Wood, Z. A., Karplus, P. A. & Poole, L. B. (2005) Analysis of the link between enzymatic activity and oligomeric state in AhpC, a bacterial peroxiredoxin. Biochemistry 44, 10583-10592. 86.Papinutto, E, Windle, H. J., Cendron, L., Battistutta, R. Kelleher, D. & Zanotti, G. (2005) Crystal structure of alkyl hydroperoxide-reductase (AhpC) from Helicobacter pylori. Biochim Biophys Acta. 1753, 240-246. 87.Wood, Z. A., Schroder, E., Harris, J. R. & Poole, L. B. (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28, 32-40. 88.Wood, Z. A., Poole, L. B. & Karplus, P. A. (2003) Peroxiredoxin evolution, The regulation of hydrogen peroxide signaling. Science 300, 650-653. 89.Jang, H. H., Lee, K. O., Chi, Y. H., Jung, B. G., Park, S. K., Park, J. H., Lee, J. R., Lee, S. S., Moon, J. C., Yun, J. W. et al. (2004) Two enzyme in one: Two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell 117, 625-635. 90.Moon, J. C., Hah, Y. S., Kim, W. Y., Jung, B. G., Jang, H. H., Lee, J. R., Kim, S. Y., Lee, Y. M., Jeon, M. G. & Kim, C. W. et al. (2005) Oxidative stress-dependent structural and functional switching of a human 2-cys peroxiredoxin isotype II that enhances HeLa cell resistance to H2O2-induced cell death. J. Biol.Chem. 280, 28775-28784. 91.Jang, H. H., Kim, S. Y., Park, S. W., Jeon, H. S., Lee, Y. M., Jung, J. H., Lee, S. Y., Chae, H. B., Jung, Y. J., Lee, K. O., et al. (2006) Phosphorylation and concomitant structural changes in human 2-cys peroxiredoxin isotype I differentially regulate its peroxidase and molecular chaperone functions. FEBS Lett. 580, 351-355. 92.Giese, K. C., Basha, E., Catague, B. Y. & Vierling, E. (2005) Evidence for an essential function of the N terminus of a small heat shock protein in vivo, independent of in vitro chaperone activity. Proc. Natl. Acad. Sci. USA. 102,18896-18901. 93.Woo, H. A., Jeong, W., Chang, T. S., Park, K. J., Park, S. J., Yang, J. S., Rhee, S. G. (2005) Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-Cys Peroxiredoxins. J. Biol. Chem. 280, 3125-3128. 94.Biteau, B., Labarre, J. & Toledano, M. B. (2003) ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 425, 980-984. 95.Emst, P. (1999) Review article: the role of inflammation in the pathogenesis of gastric cancer. Aliment Pharmacol. Ther. 13, 13-18. 96.Du, R. J. & Ho, B. (2003) Surface localized heat shock protein 20 (HsIV) of Helicobacter pylori. Helicobacter 8, 257-267. 97.Chaturvedi, R., Cheng, Y., Asim, M., Bussiere, F. I., Xu, H., Gobert, A. P., Hacker, A., Casero, R. A., Jr. & Wilson, K. T. (2004) Induction of polyamine oxidase 1 by Helicobacter pylori causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization. J Biol Chem 279, 40161-40173 98.Yan, J., Kumagai, T., Ohnishi, M., Ueno, I. & Ota, H. (2001) Immune response to a 26-kDa protein, alkyl hydroperoxide reductase, in Helicobacter pylori-infected Mongolian gerbil model. Helicobacter 6, 274-282. 99.Chuang, M. H., Wu, M. S., Lin, J. T. & Chiou, S. H. (2005) Proteomic analysis of proteins expressed by Helicobacter pylori under oxidative stress. Proteomics 5, 3895-3901. 100.Chuang, M. H., Wu, M. S., Lo, W. L. Lin, J. T., Wong, C. H. & Chiou, S. H. (2006) The antioxidant protein alkylhydroperoxide reductase of Helicobacter pylori switches from a peroxide reductase to a molecular chaperone function. Proc Natl Acad Sci U S A. 103, 2552-2557. 101.Chuang, M. H., Wu, M. S., Lo, W. L. & Chiou, S. H. (2006) Diagosis of gastro-duodenal diseases, a new way is developed by using different forms of Alkyl- hydroperoxide reductase, AhpC from Helicobacter pylori. Gastroenterology (submitted) | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34253 | - |
dc.description.abstract | 幽門桿菌是一種主要為螺旋狀形態且生長緩慢的微耗氧性(5 % O2)革蘭氏陰性桿菌。由於諸多的研究已闡明了此菌是造成部份重要的腸胃疾病如胃炎、胃潰瘍、十二指腸潰瘍甚至是胃癌的主要元兇,所以世界衛生組織已將此菌列為第一類的致癌物。於2005年更將諾貝爾醫學獎頒給「揭示胃炎及消化性潰瘍係感染幽門螺旋桿菌引發的」的兩位澳洲籍科學家巴利.馬歇爾和羅賓.華倫,所以瞭解幽門桿菌對世人的重要性可見一斑。它感染於人體的胃部後引發人體免疫系統的活化而大量釋放出活性氧分子(ROS),而這樣的反應似乎在此菌的殘存寄生與相關腸胃疾病的致病性上扮演十分重要的角色。
本研究的目的就是要探討過氧化環境對此菌的生理影響並進一步闡明相關蛋白質體表現的變化與作用機制。經由蛋白質體學方法的研究,我們已鑑定出11個蛋白質體,其中AhpC與UreE這兩種蛋白質於長時期曝露在高氧濃度(20% O2)的環境下其原有的特性會大幅地改變。此外,同源性研究的比對結果有趣地顯示出此AhpC蛋白與哺乳動物(包含人類) Prx無論在氨基酸序列、結構與酵素作用特性的相似度上皆遠高於與其他革蘭氏陰性菌的AhpC的比較結果。除此之外,在功能變化上的研究,我們也首次發現它是一種具有兩種功能的蛋白,在正常微耗氧或曝露在空氣中短時期(8小時以內)的狀況時,此蛋白保有一般正常的過氧化物還原酵素的功能,在這樣的狀態下它的結構以主要為dimer的LMW oligomers形式存在。可是,當曝露的時間過長(16小時以上)或細胞本身受傷的程度擴大時,此蛋白會藉由Trx的作用由多個oxidized-AhpC monomer分子聚合而成分子量大於660 kDa,外表呈現為立體球狀的HMW complexes,更重要的是它的功能會由原來的酵素功能完全轉變成可保護受損蛋白避免進一步變性沉積的保護子(molecular chaperone)。另外,從RT-PCR與二維電泳觀察AhpC蛋白於氧壓力下的調控與蛋白結合能力上的研究結果,發現在胃癌組織環境生存的幽門桿菌其AhpC於氧化壓力下的蛋白活性、基因表現的穩定性或是聚合後的HMW complexes的保護能力都比十二指腸潰瘍菌株好;同時由電顯之切片影像結果也顯示出胃癌組織環境的幽門桿菌較能抗氧化,且在一遇高氧壓力後會大幅表現於胞內以達到轉變為chaperone的高效率能力。所以長時期感染人體胃部並經過反覆發炎導致的ROS攻擊環境似乎不僅讓幽門桿菌發展出一套接近人體本身的基因且練就出高度抗氧化的潛力。 以此蛋白針對幽門桿菌感染相關的腸胃疾病進行血液抗體的鑑定研究,從Western- blotting與ELISA的結果顯示出胃炎與十二指腸潰瘍組織是屬於較弱的被ROS攻擊的組織,所以其所引發的抗體含量較低且辨認的AhpC蛋白為具正常構形的LMW oligomers。然而,胃潰瘍或胃癌組織其引發ROS攻擊的程度就相對很高,產生的抗體含量不僅較多外,其所辨認的AhpC蛋白的確就是HMW complexes。因此,綜合本論文的研究成果,我們相信AhpC這個在幽門桿菌內含量最多的抗氧化蛋白不僅可作為區分胃癌與十二指腸潰瘍菌株的研究起始標的以進行此二類菌株的生理特性差異的研究外,也具有在未來發展為可辨別不同腸胃疾病的醫療輔助用診斷試劑的應用潛力與價值。 | zh_TW |
dc.description.abstract | Helicobacter pylori (Hp) is a spiral, slow growing gram-negative microaerophilic bacterium. Many studies have documented Hp is the etiological agent of gastro-duodenal diseases, such as chronic gastritis, gastric and duodenal ulcers, and gastric cancer. Furthermore, World Health Organization (WHO) has classified Hp as a class 1 carcinogen. The colonization of Hp in human stomach can induce inflammatory and immune reaction to release reactive oxygen species (ROS). Such responses appear to play a pivotal role in the survival of Hp and pathogenesis of Hp-related diseases. Therefore, this study is aimed to elucidate the influence of oxidative stress on H. pylori and characterize its underlying mechanisms and protein-expression profiles. By proteomic approaches, we have identified more than 10 proteins. Among these, AhpC and UreE are greatly reduced under long-term oxidative stress. Moreover, the sequence-homology comparison showed that the alkylhydroperoxide reductase (AhpC), an abundant antioxidant protein in Hp, is more homologous to mammalian peroxiredoxins than to eubacterial AhpC. We further demonstrated that this protein can switch its structure and function from low-molecular-weight (LMW) dimer or oligomers with peroxide reductase activity under normal microaerobic conditions or short-term (< 8 h) oxidative shock to high-molecular-weight (HMW) complexes with molecular-chaperone function after severe long-term (> 16 h) oxidative stress (20% O2) in the presence of thioredoxin (Trx).
As regards the structural and functional properties of AhpC under oxidative stress, we found that AhpC isolated from the gastric-cancerous strains possesses higher protein stability and chaperone activity than that from the duodenal-ulcerous strains under stress conditions. The expression of AhpC in different strains of H. pylori generally decreases under long-term oxidative stress as revealed by 2D-PAGE and RT-PCR. AhpC expression under short-term shock actually increases, being localized in the interior of H. pylori from strains isolated from patients of gastric cancer in contrast to its distribution on the cell surface of the microorganism from strains isolated from patients of duodenal ulcer. Based on the significant difference between AhpC isolated from strains of gastric cancer and duodenal ulcer, we have applied ELISA and Western blotting to study the cross-reactivity of AhpC to antisera of H. pylori-infected patients with different pathological outcomes. The immunoassay revealed that antisera from tissues of patients with more extensive inflammation like that in patients of gastric ulcer or cancer react strongly with the HMW complexes of AhpC, whereas those from less extensive inflammation like patients of gastritis react weakly with the LMW oligomeric form of AhpC. Therefore it is conceivable that the antioxidant protein AhpC of H. pylori may prove to be useful as a diagnostic protein marker to monitor extents of tissue damages from patients of gastro-duodenal diseases infected by H. pylori. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:00:02Z (GMT). No. of bitstreams: 1 ntu-95-D92b46010-1.pdf: 5266062 bytes, checksum: 29c406bf63b3951fcdf2700ee5fa1577 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 目錄
目錄………………………………………………………………………….I 縮寫表……………………………………………………………………..VI 中文摘要………………………………………………………………..VIII 英文摘要…………………………………………………………………. XI 壹. 背景介紹……………………………………………………………….1 蛋白質體學的簡介…………………………………………………….2 蛋白質體學技術於醫學研究上的應用……………………………...7 一、 診斷醫學上的應用…………………………………………. 8 1.1免疫性蛋白質………………………………………………9 1.2體液疾病診斷………………………………………………9 1.3體液中的醣蛋白………………………………………….11 二、 毒理學及藥理學上之應用………………………………..12 2.1磷酸化作用………………………………………………..12 2.2藥物代謝物和運送……………………………………….13 2.3荷爾蒙……………………………………………………14 三、 癌症醫學上的應用………………………………………15 3.1乳癌………………………………………………………15 3.2肺癌…………………………………………………………15 3.3結腸癌……………………………………………………16 3.4腎臟癌……………………………………………………16 3.5轉移的潛力與癌症的治療……………………..…….….17 幽門螺旋桿菌(Helicobacter pylori)的簡介……………………….18 本論文研究重點…………………………………………………….25 貳. 材料與方法…………………………………………………………28 一、 實驗材料………………………………………………………28 1.1菌株與載體………………………………………………….28 1.2試藥及實驗相關酵素………………………………………28 1.3儀器設備……………………………………………………29 二、 實驗方法………………………………………………………30 2.1幽門桿菌的培養與相關生理活性測試……………………30 2.2二維電泳與影像分析……………………………………….31 2.3二維電泳膠片上之蛋白質身份鑑定分析…………………33 2.4幽門桿菌RNA的分離純化與AhpC、UreE 及其它相關白因子的基因表現分析…………………………….34 2.5幽門桿菌AhpC蛋白基因的定序…………………………...35 2.5.1-PCR amplification……………………………………….35 2.5.2-接合(Ligation)……………………………………………36 2.5.3-轉型(Transformation)…………………………………36 2.5.4-重組質體的檢定(Colony PCR)………………………36 2.5.5-定序(Sequencing)…………………………………37 2.6幽門桿菌AhpC之重組蛋白的表現與純化……………37 2.6.1-建立重組基因之保存質體菌株………………………37 2.6.2-建立重組基因之表現質體菌株………………………38 2.6.3-重組蛋白的表現與純化…………………………………39 2.7幽門桿菌AhpC重組蛋白的原態分子量之鑑定…………40 2.8幽門桿菌AhpC蛋白的同源性比較………………………40 2.9幽門桿菌AhpC蛋白之電腦模擬預測結構………………41 2.10測試用之各種AhpC蛋白的配製…………………………41 2.11 AhpC蛋白之peroxide reductase酵素活性測試……42 2.12 AhpC蛋白之分子保護子(molecular chaperone)功能…42 2.12.1-受質(substrate:insulin)的製備………………………43 2.12.2-保護子活性測定………………………………………43 2.13不同狀態下AhpC蛋白的分子大小變化測試……………43 2.13.1-聚丙醯胺膠體電泳(Native-PAGE)…………………43 2.13.2-分子篩高效率液相層析(gel-filtration HPLC)……44 2.13.3-電顯影像(EM image)…………………………………44 2.14 Far-UV圓二極光譜…………………………………………45 2.15表面疏水性(surface hydrophobicity)螢光光譜……46 2.16 AhpC蛋白於過氧狀態下保護細胞內蛋白功能 的體外測試…………………………………………………..47 2.17不同環境下幽門桿菌內AhpC蛋白的表現 與結構的差異………………………………………………..48 2.17.1-幽門桿菌樣本的製備………………………………48 2.17.2-1D-和2D-PAGE…………………………………………48 2.17.3-西方點墨法 (Western blotting)……………………..48 2.18電顯切片觀察蛋白的表現位置 (Immunogold localization)………………………………..50 2.19 AhpC蛋白的大量表現對過氧環境之 抵抗關係活體測試………………………………………….52 2.20酵素結合免疫吸附法(ELISA)………………………….53 2.21西方點墨法(Western blotting)………………………..54 參. 實驗結果與討論………………………………………………55 一、 過氧壓力下幽門桿菌的生理變化探討與 相關蛋白質體表現變化之鑑定………………………… …55 1.1幽門桿菌的生理變化分析……………………………55 1.2長時間過氧壓力下之幽門桿菌的蛋白質體 圖譜變化的分析………………………………………….. 60 1.3過氧壓力下幽門桿菌內特定基因的 表現變化分析………………………………………………64 二、 AhpC蛋白基因的定序、電腦模擬之預測結構、同 源性比較與重組蛋白質體的表現………………………….69 2.1幽門桿菌AhpC蛋白基因的定序………………………69 2.2幽門桿菌AhpC蛋白之電腦模擬預測結構………70 2.3幽門桿菌AhpC蛋白之同源性比較………………………72 2.4幽門桿菌AhpC重組蛋白的表現、純化與鑑定……75 三、 AhpC重組蛋白的基本性質鑑定………………………77 3.1 AhpC蛋白聚合體分子量及聚合數鑑定………………77 3.2 AhpC蛋白聚合體之過氧化物環原酶酵素活性分析79 四、 幽門桿菌AhpC蛋白之正常與過氧狀態之 結構與功能變化的體外測試與鑑定…………………….…82 4.1 AhpC蛋白的功能變化研究………………………………82 4.2 AhpC蛋白保護功能的體外測試研究…………………85 4.3 AhpC蛋白的分子狀態與大小的變化研究……………87 4.4 AhpC蛋白於過氧化後分子內Cystine雙硫鍵 的組成變化探討…………………………………………..…91 4.5 AhpC蛋白於過氧化後分子二級與 三級結構的變化分析……………………………………….93 五、 幽門桿菌胃癌株與十二指腸潰瘍株體內AhpC蛋白在過氧壓力環境下的抗氧化應付能力差異之比 較……………….......................................................... 96 六、 幽門桿菌胃癌株與十二指腸潰瘍株體內氧壓 AhpC蛋白在過的抗氧化應付能力差異之比較………..100 6.1幽門桿菌胃癌株與十二指腸潰瘍株體內氧化 AhpC蛋白於過環境下的續存變化比較…………….….101 6.2幽門桿菌胃癌株與十二指腸潰瘍株在不同 曝露時間的過氧環境下體內AhpC蛋白的 保護功能變化分析………………………………………. 102 6.3幽門桿菌胃癌株與十二指腸潰瘍株在過AhpC 氧環境下體內蛋白的所在位置變化分析……………….105 七、 幽門桿菌AhpC蛋白在醫療診斷上的應用研究………108 7.1 AhpC與不同腸胃疾病的病人血清之間 的免疫測定(ELISA)…………………………………….…108 7.2 AhpC與不同腸胃疾病的病人血清之間的免疫測定 (Western- blotting)…………………………………..……111 肆. 結論與未來展望……………………………………………………114 伍. 參考資料…………………………………………………………….120 陸. 附錄…………………………………………………………………134 作者簡歷…………………………………………………………………149 Publications……………………………………………………………..150 | |
dc.language.iso | zh-TW | |
dc.title | 幽門桿菌烷基-過氧化物還原酶:氧壓力環境下的蛋白質體分析及其功能的研究 | zh_TW |
dc.title | Alkylhydroperoxide Reductase (AhpC) of Helicobacter pylori:Proteomic Analysis and Functional Characterization under Oxidative Stress | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 翁啟惠,吳明賢,吳世雄,張文章 | |
dc.subject.keyword | 幽門桿菌,活性氧,蛋白質體學,同源性,蛋白保護子,電顯,胃癌,十二指腸潰瘍,診斷試劑, | zh_TW |
dc.subject.keyword | Helicobacter pylori,Proteomics,oxidative stress,2D-PAGE,RT-PCR,TEM,Western blotting,ELISA,gastric cancer,duodenal ulcer,molecular chaperone,homology, | en |
dc.relation.page | 152 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-06-27 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 5.14 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。